Prevalence of congenital haemophilia A and B in Spain in 2013, described as proportion (%) of patients in the total population (extracted from the last available census of the Spanish population for the regions considered for the study) [ Time Frame: Assessed at study visit (day 1) ] [ Designated as safety issue: No ]

Severity (mild, moderate or severe) of congenital haemophilia A and B in Spain during 2013, described as proportion (%) per category of the total number of patients with haemophilia A or B [ Time Frame: Assessed at study visit (day 1) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Mean current age at the time of visit to the HTC in 2013 [ Time Frame: Assessed at study visit (day 1) ] [ Designated as safety issue: No ]

Patients will not be treated with any specific product. Data collection only.

Eligibility

Genders Eligible for Study:

Male

Accepts Healthy Volunteers:

No

Sampling Method:

Non-Probability Sample

Study Population

Patients in active follow-up in HTCs (Haemophilia Treatment Centres) will be included in this study. A patient is considered as active if a visit to the HTC is performed in the period of January 2013 to December 2013.

Criteria

Inclusion Criteria:

Informed consent obtained before any study-related activities. (Study-related activities are any procedure related to recording of data according to the protocol)

Male patients of any age diagnosed with congenital haemophilia A or B who visited their HTC at least once during the period of January 2013 to December 2013

Exclusion Criteria:

Previous participation in this study

Female patients

Acquired haemophilia

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01959555